ADARx will present interim Phase 1 data for ADX-038, an siRNA targeting complement factor B, at ASN Kidney Week on November 7. No efficacy or safety metrics were disclosed ahead of the poster. Still, the company has already initiated multiple Phase 2 studies across IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and geographic atrophy secondary to AMD.
The core development is an accelerated, multi-indication push behind a single systemic complement inhibitor. ADX-038 is designed to silence hepatic production of factor B, aiming for durable suppression of the alternative pathway with infrequent subcutaneous dosing. The move to Phase 2 in parallel with initial Phase 1 readouts signals conviction in the modality and target class, which have been validated clinically by factor B and broader complement inhibitors in renal and hematologic indications. The timing and venue of the readout suggest ADARx intends to anchor the renal program first while keeping optionality in ophthalmology and hematology.
Strategically, this is a speed-to-scale play in a crowded complementary field. With oral factor B inhibition already approved in PNH and multiple factor D, C3, and C5 programs active across renal and ocular diseases, ADARx is leaning on dosing durability, cross-indication leverage, and platform economics to carve out space. The bet is that siRNA can deliver consistent pathway suppression with simpler adherence than daily oral or intravitreal regimens, while avoiding the combinatorial complexity seen in some antibody or small-molecule strategies. The risk is class-wide: systemic complement inhibition increases infection vigilance, and regulators are scrutinizing safety after recent complement approvals in ophthalmology and hematology. The breadth of ADX-038’s clinical footprint amplifies both upside and execution exposure.
For sites, this portfolio approach will concentrate operational demand around complementary expertise but stretch capabilities across nephrology, hematology, and retina. Expect requirements for vaccination and infection monitoring, centralized complement biomarker assays, and harmonized pharmacodynamic sampling across protocols. Nephrology centers will watch for early signals on proteinuria reduction and eGFR slope, while hematology sites will focus on hemolysis control, transfusion independence, and breakthrough hemolysis management. Ophthalmology participation raises practical questions about the appetite for systemic therapy in GA, given the field’s recent tilt toward localized intravitreal delivery despite safety debates. CROs supporting these trials will need tight cold-chain, specialty lab integration, and flexible scheduling to accommodate infrequent dosing with intensive PD monitoring around dosing windows.
For sponsors and regulators, the cross-indication design presents a familiar tension: platform efficiency versus indication-specific rigor. If ADX-038 shows clean, durable factor B knockdown with manageable safety, regulators may permit streamlined late-stage designs in renal disease where unmet need and mechanistic fit are strongest. However, heterogeneity in endpoints—renal composite measures, LDH, and transfusion endpoints in PNH, and lesion growth in GA—means each program will rise or fall on its own data despite shared biology. The company’s broader AbbVie collaboration in siRNA across neuroscience, immunology, and oncology suggests a financing and co-development backstop if early efficacy materializes.
The immediate watchlist is the Phase 1 pharmacodynamic profile: magnitude and durability of factor B suppression, dose interval, and early safety, particularly infection signals and hepatic labs. Near-term reads from the renal Phase 2s will determine whether the program consolidates around IgAN and C3G or maintains equal weight across indications. If durability enables quarterly or less frequent dosing with robust pathway inhibition, ADX-038 could find operational traction. If safety or dosing cadence disappoints, the advantage over oral or intravitreal competitors narrows quickly. Timing of any regulatory interactions on adaptive or seamless designs will hint at how aggressively ADARx plans to prosecute the path to Phase 3.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
